Wacker Chemie invests 100 million euros in mRNA factory

By Zuzanna Szymanska

BERLIN, July 5 (Reuters) - Chemicals group Wacker Chemie WCHG.DE has commissioned construction firm Exyte to build a plant for mRNA components, a medical technology first widely used in COVID-19 vaccines, in an investment of 100 million euros ($102.97 million).

Wacker said on Tuesday the German state would pay an annual fee to reserve about half of its capacity for its pandemic preparedness programme but declined to say if and how much the state had paid for the construction.

The rest of the capacity can serve customers developing other uses for the mRNA technology including cancer therapy once the plant is completed in July 2024, Exyte said.

The chemicals maker is one of five partners that signed deals with the German government, which has earmarked 2.861 billion euros to supply the country with vaccines in any future pandemic outbreaks through 2029.

The rest of the capacity can serve other customers once the plant is completed in July 2024, Exyte said.

"The mRNA technology is a real quantum leap that will revolutionize cancer therapy, for example," Exyte Chief Executive Wolfgang Buechele told Reuters in an interview.

"With mRNA, drugs go to the exact part of the body where they are supposed to work. Now, if you take an aspirin for a headache, most of the active substance has no effect at all because it reaches places where it is not needed," he said.

Exyte builds facilities for chipmakers, drugmakers and software companies using a patented rapid modular construction system, which allows it to halve the usual construction time.

It has been focusing on its semiconductor plant business because it is the most profitable - with prices in the four- rather than three-digit million range - but it plans to grow its pharmaceutical plant business as well, Buechele said.

"Medicine is undergoing fundamental changes," said Buechele, who was the CEO at world's largest industrial gases company Linde LIN.N , LINI.DE from 2014 to 2016 before taking over as the boss of Exyte in 2017.

"This is why flexibility is more and more important when setting up production capacities," he said, adding the company aimed to double the share of drug plants in its revenue to 15% in 2027, with total sales amounting to 10 billion euros.

Exyte, whose customers include Infineon IFXGn.DE , Pfizer PFE.N , Sanofi SASY.PA and IT giants from Silicon Valley, makes 7% of sales from drug factories, while semiconductor plants make up 87% and data centres about 4%, the CEO said. ($1 = 0.9712 euros)
Reporting by Zuzanna Szymanska Editing by Madeline Chambers and David Evans

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.